Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG-022 in Advanced/Metastatic Solid Tumors
NCT05718895Phase 1Recruiting
- Sponsor
- Antengene
- Start
- Mar 2023
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ATG-022 in solid tumor, sponsored by Antengene. Primary endpoints: Dose-Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Started Mar 2023; status: recruiting.
02
Drugs
ATG-022
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05718895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05718895.